Public Summary
Drugs that inhibit viral proteins are expected to limit the spread of COVID19. While some of the viral proteins are considered good drug targets, others are more difficult. Our group has specific expertise in technology that allows the identification of drug-like molecules that bind to these challenging proteins. We are currently building these assays to enable discovery of new anti-viral drugs.